Zydus Cadila has received the tentative approval from the USFDA to market Deferasirox Tablets, 90 mg, 180 mg, and 360 mg (US RLD-Exjade Tablets). It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

It is used to treat ongoing high levels ofiron in the body caused by multiple blood transfusions.

It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non-transfusion-dependent thalassemia).

The group now has 231 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 9.65, or 2.65%, to trade at Rs 355.00. The total volume of shares traded was 42,658 at the BSE (2.41 p.m., Tuesday).